Clinical Trials Browser

INDUSTRY × Carmustine × 90 days × Clear all

NCT03382977 2026-05-08

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Phase 1/2 Terminated

Glioblastoma, Neoplasms

NCT06915246 2026-03-27

A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

Phase 2 Recruiting

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin